Insider Selling: Lantheus Holdings Inc (NASDAQ:LNTH) Director Sells $137,000.00 in Stock
Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $27.40, for a total value of $137,000.00. Following the completion of the transaction, the director now owns 42,467 shares in the company, valued at approximately $1,163,595.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Lantheus stock opened at $27.85 on Monday. The stock has a market capitalization of $1.08 billion, a P/E ratio of 29.63, a PEG ratio of 2.09 and a beta of 1.46. Lantheus Holdings Inc has a 12-month low of $12.59 and a 12-month high of $28.48. The company has a current ratio of 4.57, a quick ratio of 3.82 and a debt-to-equity ratio of 3.16.
Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.03. The business had revenue of $86.51 million for the quarter, compared to analysts’ expectations of $86.80 million. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. As a group, equities analysts predict that Lantheus Holdings Inc will post 1.11 earnings per share for the current fiscal year.
LNTH has been the topic of several recent research reports. TheStreet upgraded Lantheus from a “c+” rating to a “b” rating in a report on Monday, March 4th. BidaskClub cut Lantheus from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 11th. Finally, Zacks Investment Research upgraded Lantheus from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a report on Thursday, April 4th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $23.33.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Read More: Why is cost of goods sold important?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.